Notably, a combination of Ca2+ activator curcumin, FBXL2 activator nebivolol, and osimertinib significantly inhibits EGFRT790M/C797S-driven TKI-resistant NSCLC growth. This evidence concerns the gene FBXL2 and non-small cell lung carcinoma.